Compare Celgen Biopharmaceuticals vs Kythera Biopharmaceuticals
Customers evaluate the quality of Celgen Biopharmaceuticals's products using the following success metrics.
Overview
Celgen Biopharmaceuticals is based in China
Shanghai Celgen Biopharmaceutical is a bio-similar biopharmaceuticals drugs developer and manufacture in China mainly focused on Inflammation, Oncology and Metabolic Disease. Celgen's main product is a Monoclonal Antibody (MAB) called Etanercept a Generic version of Amgen's Enbrel used for the treatment of inflammatory conditions such as Rheumatoid arthritis, Juvenile rheumatoid arthritis, Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis.
Kythera Biopharmaceuticals is 19 yrs old and is based in United States.
Kythera (NASDAQ: KYTH) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel prescription products for the aesthetic medicine market. The Company's objective is to develop first-in-class, prescription products using an approach that relies on the scientific rigor of biotechnology to address unmet needs in the rapidly-growing market for aesthetic medicine.
Demo Video
Leadership
Jay E. Birnbaum (Founder)
Investors
China-Israel Value Capital
Allergan, Versant Ventures
Product
Benefits
Products
Customers
Known Partners
Why They Buy
Information not available because Celgen Biopharmaceuticals has not claimed their profile.
Work for Celgen Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Celgen Biopharmaceuticals?
Claim your profile now.
Information not available because Kythera Biopharmaceuticals has not claimed their profile.
Work for Kythera Biopharmaceuticals? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for Kythera Biopharmaceuticals?
Claim your profile now.